Using Plasma Amyloid Beta Oligomer to Screen in Alzheimer’s Disease: A Pilot Study
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27020846 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Pin-Chieh Hsu und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease, Peptide Fragments. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Research Institutes Grant, Kaohsiung Medical University Research Center, Department of Neurology, Kaohsiung Medical University Gangshan Hospital.
Themen: Demenz
Abstract (Originalsprache)
Previous studies have shown that plasma amyloid-beta oligomers (AβOs), the toxic form of amyloid-beta (Aβ), are a critical issue in the development or worsening of Alzheimer’s disease (AD) and can be regarded as a blood marker for screening in dementia. We examined plasma AβOs with their related biomarkers in a case–control study to clarify these issues. A total of 16 patients diagnosed with Alzheimer’s dementia (AD) and 16 cognitively normal controls (NCs) were recruited to compare their plasma biomarkers, AβO, Aβ1-40, and Aβ1-42, also referring to other parameters like APOE ε4 status, Clinical Dementia Rating®-Sum of Boxes (CDR®-SB), and Mini Mental Status Examination (MMSE) scores. In plasma concentrations of Aβ1-40, Aβ1-42, and AβO, the mean concentrations were significantly different between the two groups. There is a significant increase in the concentrations of Aβ1-40 and AβO, while Aβ1-42 is decreased in individuals with AD compared to NC. AβO was statistically associated with the Aβ1-40 and Aβ1-42/Aβ1-40 ratio. Higher plasma concentrations of AβO were significantly associated with AD compared to non-dementia controls. This suggests that AβOs can be potential plasma biomarkers to screen in AD. However, a study recruiting more individuals is necessary to examine the association, if any.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan.
- Department of Neurology, Kaohsiung Medical University Gangshan Hospital, Kaohsiung Medical University, Kaohsiung 80756, Taiwan.
- Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80756, Taiwan.
- Neuroscience Research Center, Kaohsiung Medical University, Kaohsiung 80756, Taiwan.
ORCID-Profile: Ling-Chun Huang, Yuan-Han Yang
Förderung
- National Health Research Institutes Grant
- Kaohsiung Medical University Research Center
- Department of Neurology, Kaohsiung Medical University Gangshan Hospital
- National Health Research Institutes
- Department of Neurology at Kaohsiung Medical University Gangshan Hospital
Zitieren
APA
Hsu, P. C., Yang, J. Y., Huang, L. C., & Yang, Y. H. (2026). Using Plasma Amyloid Beta Oligomer to Screen in Alzheimer’s Disease: A Pilot Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020846
Vancouver
Hsu PC, Yang JY, Huang LC, Yang YH. Using Plasma Amyloid Beta Oligomer to Screen in Alzheimer’s Disease: A Pilot Study. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020846
BibTeX
@article{Hsu2026,
author = {Hsu, Pin-Chieh and Yang, Jia-Ying and Huang, Ling-Chun and Yang, Yuan-Han},
title = {Using Plasma Amyloid Beta Oligomer to Screen in Alzheimer’s Disease: A Pilot Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27020846}
}
EUVIMED